中美史克终结近40年合资历史！赫力昂完成全资控股

Core Viewpoint - The acquisition of the remaining 12% stake in the joint venture China-US Tianjin Schering Pharmaceutical Co., Ltd. by Heliang marks the end of a nearly 40-year partnership, allowing Heliang to fully control the company and strengthen its position in the Chinese OTC market [1][2]. Group 1: Company Acquisition - Heliang has completed the acquisition of the remaining 12% stake in China-US Tianjin Schering, making it a wholly-owned subsidiary [1]. - The acquisition process involved two transactions in September 2024, where Heliang increased its stake from 55% to 88% by acquiring shares from Darentang and Tianjin Pharmaceutical Group [1]. - The joint venture was originally established in 1987 by GSK and local partners, and Heliang became an independent company after spinning off from GSK in July 2022 [1][2]. Group 2: Market Position and Strategy - China has become the second-largest health consumption market globally, providing significant opportunities for multinational companies focused on consumer health [2]. - Heliang's full acquisition of China-US Tianjin Schering will enhance its presence in the OTC drug sector in China [2]. - The company has been expanding its regional market presence by establishing subsidiaries in cities like Chengdu, Xi'an, Shanghai, and Guangzhou to penetrate lower-tier markets [2]. Group 3: Consumer Trends and Product Development - There is an increasing demand for nutritional health products, particularly those that boost immunity, driven by rising health awareness among consumers [3]. - Heliang aims to maintain flexibility and responsiveness in a rapidly changing market, focusing on continuous innovation to build consumer trust [3]. - The OTC and nutritional health product markets are influenced by various factors, including product functionality, pricing, and brand trust, necessitating ongoing innovation to capture market share [3].